12-03-2025
MediLink Is Said to Weigh Licensing Deal Ahead of Potential IPO
MediLink Therapeutics Ltd. is exploring a licensing partnership to develop an antibody-drug conjugate with a global pharmaceutical company, according to people familiar with the situation.
MediLink is working with an adviser to sound out interest for cancer drug YL201, the people said, asking not to be identified because the deliberations are private. A deal could serve as a stepping stone toward an initial public offering, possibly in Hong Kong and as soon as 2026, the people said.
